---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-035424"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2025-07-21T23:59:59+00:00"
generated_at: "2026-05-18T05:25:23.503216+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology appoints Robert Brainin as CEO effective Aug 25, 2025

## Summary
- Robert Brainin named CEO, effective August 25, 2025; he was a Board member since Feb 2021.
- Annual base salary of $500,000; target incentive bonus of 75% of base salary.
- Equity awards: 225,000 options (4-year vest) and 475,000 performance-based options.
- Ronnie Morris, M.D., transitions to Executive Chairman; Joel Ackerman becomes Director.
- Brainin brings 25+ years life sciences/tech experience; most recently CBO at Veracyte.

## SEC filing metadata
- accession: 0001628280-25-035424
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2025-07-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828025035424/0001628280-25-035424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828025035424/csbr-20250721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-035424
- JSON: https://secwatch.observer/filing/0001628280-25-035424.json
- Plain text: https://secwatch.observer/filing/0001628280-25-035424.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.